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be	 considered.	An	 algorithm	 for	 diagnosis	 of	 FXIIID	 including	different	 approaches	
dependent	upon	laboratory	capability	is	proposed.
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1  | INTRODUCTION








country-	specific,	 facilitating	methods	 to	 confirm	FXIIID	diagnosis	 in	
such	areas.2-4
Signs	 and	 symptoms	of	FXIIID	 range	 from	 life-	threatening	hem-
orrhage	such	as	intracranial	hemorrhage	to	mild	forms,	including	skin	
bleeding.	Umbilical	 cord	bleeding	and	soft	 tissue	hematoma	are	 the	
most	common	and	often	the	 first	symptom	of	FXIIID.3,5,6 In women 
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assays	are	required.	FXIIID	remains	one	of	the	most	underdiagnosed	
rare	 bleeding	 disorders.10-12	Although	 comprehensive	 guidelines	 for	
FXIIID	 diagnosis	 have	 been	 published	 by	 the	 International	 Society	
on	 Thrombosis	 and	 Haemostasis	 Scientific	 and	 Standardization	
Committee	(ISTH-	SSC),	these	have	not	been	implemented	uniformly	
worldwide	due	to	insufficient	laboratory	assay	resources.13	However,	

















and	 to	propose	 an	 algorithm	 that	may	be	 considered	 to	 improve	di-
agnostic	 efficiency	 and	 prevent	missed	 or	 delayed	 FXIIID	 diagnosis,	
thereby	reducing	morbidity	and	mortality	of	patients	with	this	disease.
2  | RESULTS
2.1 | Assays used to measure FXIII activity
Assays	to	measure	FXIII	activity	are	based	on	the	transglutaminase	re-
action	catalyzed	by	FXIII	after	its	activation,	which	is	described	below.










site	 cysteine	 residues,	which	 react	with	 fibrin	monomers	 catalyzing	
their	cross-	linking.3,12,15


















In	 addition	 to	 cross-	linking	 gamma	 chain	 fibrin	 molecules,	 acti-
vated	 FXIII	 can	 attach	 the	 fibrinolytic	 inhibitor	 (α2	 antiplasmin)	 to	
alpha	chain	fibrin	molecules	to	prevent	premature	degradation	of	the	
formed	clot	by	fibrinolysis	via	plasmin.10,16








also	 indicate	 specific	 deficiencies,	 including	 FXIIID.3,6,17,18	 Clinical	




























The	 advantages	 of	 the	CST	 are	 that	 it	 is	 easy	 to	 perform,	 inex-
pensive,	 and	without	 specific	 instrumentation	 requirements,	 so	 that	
it	 can	 be	 established	 in	 most	 laboratories.	 However,	 disadvantages	
include	a	 lack	of	 standardization	and	 low	sensitivity	 (inability	 to	de-




a	 routine	screening	 test	 for	 the	aforementioned	 reasons,	 the	CST	 is	
often	the	first	screening	test	utilized	in	many	coagulation	laboratories	
in	developing	countries	as	well	 as	 in	20%	of	developed	countries.10 
Apart	from	resource	issues,	the	lack	of	regulatory	approval	for	some	












































FXIII levels (%) Comment
CaCl2 Urea <0.5-	5 More	specific	than	acetic	acid-	based	assay
Thrombin Acetic	acid 10 Sensitive	and	rapid,	but	less	specific	than	
urea-	based	assay















is	 abnormal.	The	establishment	of	 a	 local	 cutoff	 solubility	 time	may	
also	be	of	advantage	to	optimize	this	strategy.
2.2.2 | Quantitative assays (functional activity 
assays)
Quantitative	 FXIII	 activity	 assays	 are	 recommended	 as	 first-	line	
screening	tests	whenever	possible.	Three	main	methods	are	used	to	
measure	 FXIII	 activity	 levels,	 all	 currently	 based	 upon	 the	 transglu-
taminase	 reaction	 in	 the	 cross-	linking	 process:	 (i)	 ammonia	 release	














estimation.3,16	 The	 cause	 of	 this	 increased	 activity	 is	 FXIIIa-















•	 In	 the	amine	 incorporation	assay,	 fluorescent,	 radiolabeled,	or	bi-
otinylated	 amines	 covalently	 bound	 to	 a	 glutamine	 residue	 of	 a	
substrate	 are	 measured	 after	 free	 unbound	 amines	 have	 been	
separated	from	the	protein-bound	fraction.	Although	amine	incor-
poration	assays	are	more	sensitive	than	the	ammonia	release	assay,	
they	 are	more	difficult	 to	 standardize,	 have	difficulty	with	 repro-
ducibility,	and	are	time-consuming.	Moreover,	certain	types	of	this	
assay	that	measure	transglutaminase	activity	at	the	initial	stage	of	









a	 fluorophore.16	 Although	 overestimation	 does	 not	 occur	 in	 this	
assay,	the	limit	of	quantitation	is	around	5%	normal	FXIII	activity;	
therefore,	it	is	less	sensitive	than	other	FXIII	activity	assays.16
2.2.3 | Immunological assays (FXIII antigen assays)
A	FXIII	 antigen	 assay	 is	 required	 for	 the	 classification	of	FXIII	 defi-




FXIII-	B,	 and	 the	FXIII-	A2B2	 complex.	Clearly,	 one	 limitation	 to	 anti-
gen	 assays	 is	 that	 they	may	 fail	 to	 identify	 rare	qualitative	 (type	 II)	
deficiencies,	 in	which	the	FXII-	A	enzyme	 is	present	but	 functionally	
defective.12	 Although	 assays	 for	 the	measurement	 of	 the	 different	
FXIII	subunits	are	available,	some	centers	may	only	use	the	most	fre-
quently	employed	FXIII-	A	ELISA,	thereby	not	complying	with	current	
recommendations	 and	 potentially	 missing	 the	 rarer	 FXIII-	B	 subunit	
deficiency.
Electroimmunoassays	 (EIA),	 radioimmunoassays	 (RIA),	 latex-	
enhanced	 immunoprecipitation	 assays,	 or	 enzyme-	linked	 immuno-
sorbent	assays	(ELISA)	are	four	common	immunoassay	methods;	with	
ELISA	considered	superior	to	other	methods.	Several	types	of	ELISA	
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FXIII	 deficiency;	 these	 cannot	 be	 differentiated	 using	 quantita-
tive	 assays.	 Inhibitor	 assays	 are	 performed	 to	 determine	 whether	
FXIIID	in	a	patient	is	hereditary	or	due	to	formation	of	an	autoanti-
body	recognizing	FXIII.	The	development	of	a	FXIII	autoantibody	 is	
a	 very	 rare	 event,	with	 less	 than	100	 cases	worldwide	 reported	 to	
date26.	Approximately	50%	of	cases	are	 idiopathic,	whereas	under-
lying	diseases	 related	 to	an	 imbalance	of	 the	 immune	system,	 such	
as	 autoimmune	 disorders,	 solid	 neoplasms,	 myeloproliferative	 and	
lymphoproliferative	 diseases,	 prolonged	 drug	 use,	 and	 pregnancy,	
are	also	associated	with	the	development	of	autoantibodies	against	
FXIII.	Autoimmune	FXIII	deficiency	occurs	mainly	in	older	adults	and	
can	 result	 in	drastically	decreased	FXIII	 levels,	with	potentially	 life-	
threatening	 bleeding.	 Clinical	 symptoms	 cover	 a	 large	 range	 from	
common	 multiple	 mucocutaneous	 or	 intramuscular	 bleeds	 to	 life-	
threatening	 internal	hemorrhages.26	Older	adults	with	a	 recent	and	
spontaneous	onset	of	bleeding	symptoms	lacking	previous	bleeding	










arrangements.10,13	The	use	of	 an	 inhibitory	 assay	 is	 age-	dependent	
and	not	recommended	for	FXIIID	evaluation	when	diagnosed	at	birth,	




2.2.5 | FXIII molecular (genetic) analysis









FXIIID	 cases.	The	B	 subunit	 gene	 is	 located	on	 chromosome	1	 and	









subunits.	 Five	 common	 coding	 polymorphisms	 have	 been	 detected	
in	 the	 FXIII-A	 gene	 and	 affect	 either	 FXIII	 activity	 or	 plasma	 level:	
Val34Leu	(the	most	common;	accelerated	FXIII	activation),	Tyr204Phe	
(decreased	FXIII	plasma	level	and	activity),	Pro564Leu	(decreased	FXIII	




developed	and	developing	countries,	 is	 shown	 in	Table	4.27	 In	 some	
countries,	 molecular	 analysis	 can	 facilitate	 diagnosis	 if	 population-	
specific	 mutations	 are	 known.	 Based	 on	 this	 knowledge,	 genetic	








This	strategy	may	be	useful	 in	countries	 in	which	highly	specific	 re-
current	mutations	are	common;	it	will	not	detect	spontaneous	novel	
mutations.	An	example	where	this	strategy	has	been	employed	is	Iran,	
where	 nearly	 one-	third	 of	 all	 patients	 with	 FXIIID	 worldwide	 have	
been	 reported.	 Two	 mutations	 are	 found	 commonly,	 of	 which	 one	
(c.562T>C)	was	detected	in	95%	of	affected	patients.29,30	Using	this	
approach,	identified	FXIIID	cases	increased	more	than	twofold	within	
2	years	 from	2014	 (217	 registered	patients,	 annual	 report	 of	WFH)	
to	2016	(483	patients).29,31	In	addition,	FXIII-	targeted	genetic	analysis	
TABLE  3 FXIII	activity	and	antigen	levels	in	the	presence	of	autoantibody	[adapted	from13]
FXIII- autoantibody Plasma FXIII activity
Plasma FXIII- A2B2 
antigen
Plasma FXIII- A 
antigen












Non-	neutralizing	antibody Severe	decrease	(FXIII-	A) Severe	decrease Severe	decrease Decrease	(>30%) NL NL
B
Non-	neutralizing	antibody Severe	decrease	(<3%) Severe	decrease Severe	decrease Severe	decrease NL NL
FXIII,	factor	XIII;	FXIII-	A,	factor	XIII	subunit	A;	FXIII-	A2B2,	factor	XIII	A2B2-	heterotetramer;	FXIII-	B2,	factor	XIII	B2-	homodimer;	NL,	normal	level.




















Developing or emerging 
country Developed country































Patient history Family history
Positive family history or patient history of umbilical cord stump bleeding, delayed umbilical 
detachment, intracranial bleeding, subcutaneous bleeding, any other abnormal bleeding history or 
recurrent miscarriage
Highly suggestive of FXIII 
deficiency*
Routine hemostasis assays:
aPTT, PT, PFT, platelet countAbnormal Normal
Other coagulation or 
platelet function disorders
Clinical evaluation
Well-equipped coagulation laboratory Less well-equipped coagulation 
laboratory**
1. Clot solubility test
(using 2 methods in parallel)







2. FXIII activity and 
antigen assays§§
3. FXIII-A and FXIII-B antigen measurement
4. Autoantibody assay†





Rapid FXIII deficiency 
diagnosis allowing for rapid 
treatment
OR§
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rates	of	morbidity	and	mortality.	False-	positive	platelet	function	tests	
may	contribute	to	missed	or	delayed	diagnosis	of	FXIIID.	Symptoms	
of	 severe	 umbilical	 cord	 bleeding,	 intracranial	 hemorrhage,	 and	 he-
marthrosis	are	unusual	in	patients	with	platelet	function	disorders.17
Specific	 common	 and	 recurrent	mutations	 in	 geographic	 areas	
due	 to	 founder	 effects	 may	 facilitate	 diagnosis	 through	 estab-
lishment	 of	 targeted	 genetic	 testing;	 if	 targeted	 genetic	 tests	 are	
available	 in	 reference	 laboratories,	 diagnosis	 may	 be	 established	
more	 rapidly,	 especially	 if	 specific	 functional	 tests	 are	 not	 readily	





CST	greatly	 improved	identification	of	affected	cases	 in	this	area.2 
In	 geographic	 regions	with	 a	 known	elevated	 incidence	of	 FXIIID,	
















approaches	 based	upon	 local	 coagulation	 laboratory	 availability	 and	
capability	for	FXIII	assays	is	proposed	(Figure	2).





utilized	 ammonia	 release	 assay,	 even	 in	well-	equipped	 laboratories,	
most	specifically	in	the	low	activity	ranges;	the	use	of	a	plasma	blank	
minimizes	this	effect	and	allows	differentiation	of	severe	cases.	Less	
well-	equipped	 laboratories,	without	 the	capacity	 to	perform	quanti-
tative	assays,	may	use	CST	in	conjunction	with	country-	specific	cen-
tralized	 targeted	mutation	analysis	or	FXIII	 activity	measurement	 to	
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